INTRODUCTION
Intestinal lymphangiectasia is a chronic congenital or acquired disorder of lymphatics associated with proteinlosing gastroenteropathy (1) . Patients with this disease have marked hypoproteinemia and edema which is often asymmetrical. The characteristic morphologic lesion of intestinal lymphangiectasia is dilated lymphatic channels in the mucosa of the small bowel. Peripheral lymphatic abnormalities may also be demonstrated by lymphangiography and 45% of the patients develop chylous effusions.
An immune deficiency state with abnormalities of both the humoral and cellular immune systems is associated with intestinal lymphagiectasia (2) . Concentrations of IgG, IgA, and IgM are reduced as a result of excessive gastrointestinal protein loss while immunoglobulin synthetic rates are normal. A more marked deficiency of the cellular immune system, as assessed by either intradermal delayed hypersensitivity skin tests or skin allograft survival, is characteristically seen. These findings are associated with a significant peripheral lymphocytopenia which is presumably also due to loss of lymphocyte-rich lymph into the gastrointestinal tract.
The cellular immune deficiency of intestinal lymphangiectasia could be due to the reduced numbers of peripheral blood lymphocytes, in which case one would expect the residual lymphocyte population to function normally in vitro. Alternatively, the anergy could re-sult from qualitative as well as quantitative changes within the lymphocyte population, such as relative de- pletion of a necessary subpopulation of lymphocytes, in which case one would expect the residual lymphocyte population to be deficient in vitro. We have attempted to distinguish between these alternatives by studying in vitro lymphocyte transformation of peripheral blood and chylous fluid lymphocytes to a variety of mitogenic stimuli. These studies provide evidence which strQngly favors the second alternative, and support the concept that there are at least two functionally distinct lymphocyte populations in man.
METHODS

Patients studied
Data obtained from 12 patients with intestinal lymphangiectasia are included in this study. All patients had significant protein-losing enteropathy manifested by hypoalbuminemia and edema and documented by excessive fecal loss of albumin-'Cr (3) . In addition, all of the patients had one and usually two or more of the following signs of lymphatic abnormality: lymphocytopenia, dilated lymphatics on intestinal biopsy, abnormal lymphangiogram, chylous effusions, asymmetrical edema, and cutaneous lymphangiomata. In no patient did careful clinical evaluation reveal evidence of any other disorder associated with protein-losing gastroenteropathy (1), and in particular other gastroenteropathies associated with lymphocytopenia (Whipple's disease, regional enteritis, and constrictive pericarditis) were excluded.
The patients ranged in age from 11 to 81 yr; the average duration of disease was 17 yr. They were clinically stable during the periods of study and were free of acute disease, infection, or malignancy. Tests of liver and renal function were generally normal. Associated diseases were limited to one patient each with diabetes mellitus, arteriosclerotic peripheral vascular disease, pulmonary emphysema, and morphea. Drug therapy was limited to diuretics.
Lymphocyte blast transformation in vitro
Culture conditions. Lymphocyte transformation was performed as previously described (4) with several modifications. Leukocyte-rich plasma from heparinized peripheral blood was obtained by gravity sedimentation. The number of mononuclear cells was determined by counting in a standard hemocytometer chamber using 0.02% crystal violet in 2%o acetic acid as diluent. Duplicate 1 ml cultures containing 5 X 10' mononuclear cells were established in medium RPMI-1640 with 2 mm glutamine, 100 U penicillin, and 100 Ag streptomycin/ml and 10%o autologous or homologous plasma. In some early experiments Eagle's minimal essential medium1 and 20%o plasma were used. In most experiments, cells were cultured in autologous plasma and were therefore not washed, but if cells were to be cultured in homologous plasma, they were washed three times at 4°C with plasmafree medium before counting. In multiple control experiments conducted throughout the duration of these studies, no consistent differences in responses were obtained in autologous plasma compared with normal homologous plasma (individual or pooled) and no inhibitor of normal lymphocyte transformation was found in the plasma of patients with Harvesting protocol and expression of results Cell suspensions were pulsed with thymidine-'H for the final 41 hr of the culture period and the acid precipitable radioactivity determined as described by Oppenheim, Wolstencroft, and Gell (6) . Results of duplicate determinations usually agreed within 20% and were averaged. The dpm of the unstimulated culture was then subtracted from the dpm of each stimulated culture to obtain the increment in dpm attributable to the stimulants. Results are expressed as the per cent response of the patient relative to the control individuals' response for each stimulant on each day studied. Six patients were studied on more than one occasion. So 'Dryvax, Wyeth Laboratories, Philadelphia, Pa. 1 Westinghouse Electric Corp., Baltimore, Md.
as not to weigh these multiple determinations excessively, the geometric mean of the several determinations of any single stimulant for each patient was calculated and used as the value for this patient.
Lymphocyte counts and serum albumin
Total white blood cell and differential counts were obtained using standard hemotological techniques and the absolute lymphocyte count calculated using the expression, WBC count X per cent lymphocytes equals absolute lymphocyte count. Serum albumin concentrations were determined either by the bromcresol green method (7) or by electrophoresis. Absolute lymphocyte counts and serum albumin concentrations for each patient represent the mean of at least three determinations during the period studied.
RESULTS
In vitro lymphocyte transformation to nonspecific mitogens. Lymphocytes may be stimulated in vitro to undergo blast transformation by a wide variety of stimulants including some which do not require prior sensitization of the lymphocyte donor (8, 9) . These latter stimulants have been termed "nonspecific mitogens." Lymphocytes from patients with intestinal lymphangiectasia show markedly impaired reactivity to three nonspecific mitogens, PHA, SF, and PWM, (Fig. 1) , with mean responses of 22-39% of normal Furthermore, in only one patient was the response to a single nonspecific mitogen normal; all other determinations were less than 66% of normal.
In vitro lymphocyte transformation to specific antigens. Another class of mitogenic stimulants are the specific antigens, which require prior sensitization of the donor with an antigen in order for his lymphocytes to be stimulated to undergo proliferation when exposed to that antigen in vitro (8, 9) . As shown in Fig. 2 , patients with intestinal lymphangiectasia also show markedly deficient in vitro transformation to all specific antigens. Only 2 of 46 determinations equal or exceed control responses, while 32 are less than 25% of normal. Some caution is necessary in interpreting any individual value, since these results are expressed as a per cent of the response of control individuals and the previous exposure of both patients and controls to any particular antigen is uncertain. Nevertheless, the consistently low responses of the patients with intestinal lymphangiectasia as a group is evident and is not likely to be due solely to chance differences in antigenic exposure.
In vitro lymphocyte transformation to allogeneic cells. A third class of stimulants of in vitro lymphocyte proliferation are allogeneic cells, which are specific stimulants but do not require prior sensitization of the lymphocyte donor to allogeneic antigens (8 tact sensitivity to dinitrochlorobenzene, and reduced ability to reject skin allografts from unrelated donors.
These immune abnormalities in intestinal lymphangiectasia are associated with lymphocytopenia which appears to be the result of loss of lymphocytes into the gastrointestinal tract. Evidence for this mechanism of lymphocytopenia includes the following: (a) all of the proteinlosing gastroenteropathies associated with lymphocytopenia have demonstrable lymphatic abnormalities (10) (11) (12) , while the nonlymnphocytopenic protein-losing gastroenteropathies do not (13) (14) (15) ; (b) in the lymphocytopenic protein-losing gastroenteropathies in which the protein loss is reversible, the lymphocytopenia is also reversible (11, (16) (17) ; (c) lymphatic fluid has been shown to leak directly into the bowel lumen in some patients with intestinal lymphangiectasia, either by aspiration of chyle from the duodenum (18, 19) or by the appearance in the bowel lumen of contrast medium administered during lymphangiography (18, 20) Thus it appears that patients with intestinal lymphangiectasia do lose lymphocytes as well as serum proteins into the gastrointestinal tract, most probably as part of the bulk loss of lymph fluid containing both cellular elements and serum proteins. The in vitro studies of lymphocyte function reported here were undertaken to assess whether the cellular immune defect observed in these patients is simply the result of the reduced number of peripheral blood lymphocytes. We have seen however, that even when cultures were established with equal numbers of mononuclear cells, lymphocytes from patients with intestinal lymphangiectasia still showed impaired in vitro transformation to all xnitogens. If the immune deficiency of intestinal lymphangiectasia were solely the result of the quantitative decrease in lymphocyte number, these conditions of in vitro study should correct the deficiency. Since this is not the case, the residual lymphocyte population of patients with intestinal lymphangiectasia must be qualitatively as well as quantitatively defective.
A qualitative defect could occur as a result of the production of defective lymphocytes. However, this possibility is unlikely in view of the fact that in vitro lymphocyte reactivity was roughly correlated with the magnitude of protein loss into the gastrointestinal tract, a process which would not be expected to affect lymphocyte function directly. Furthermore, patients with intestinal lymphangiectasia can produce responsive lymphocytes, as shown by the increased reactivity of the cells in the chylous fluid. A more likely explanation for the qualitative lymphocyte defect lies in the possibility that the peripheral lymphocyte pool in man is a functionally heterogeneous population of cells, and that the intestinal lymphocyte loss in these patients preferentially affects those cells which normally participate in proliferative responses in vitro.
The concept of functional heterogeneity of the peripheral lymphocyte pool is supported by a large body of experimental evidence which indicates that the peripheral blood lymphocyte pool of rodents consists of at least two distinct cell populations (21, 22 (23) (24) (25) (26) (27) .
In particular, Iversen (27) has shown that peripheral blood lymphocytes obtained from rats after several days of thoracic duct drainage and hence relatively depleted in recirculating lymphocytes proliferate poorly in vitro to PHA. At the same time thoracic duct lymphocytes, comprised primarily of cells in the recirculating population, respond significantly better. Thus, in the experimental animal, the long-lived, recirculating lymphocyte or its recent progeny appears to be largely responsible for in vitro lymphocyte transformation. In intestinal lymphangiectasia, the loss of lymphocyterich lymph into the gastrointestinal tract would significantly affect only cells which enter the lymph, i.e. the recirculating lymphocyte population, while nonrecirculating cells which are not likely to be present in intestinal lymph would not be affected. The effect of chronic gastrointestinal loss of lymphocytes upon the recirculating population could be profound, especially if this population consists primarily of long-lived cells. For example,' if 20% of the recirculating lymphocytes were lost daily 12 The effect of a bulk loss process on lymphocytes with different life spans can be determined from the following kinetic considerations which have as their basic assumption that the rate of synthesis and delivery of lymphocytes is not altered secondary to the bulk loss process. If lymphocytes are normally randomly eliminated from the recirculating pool, the size of this recirculating pool can be estimated from the equation P1 = si/k1, where P1 = the number of lymphocytes in the recirculating pool, si = the number of lymphocytes synthesized and delivered into the pool daily, and k1 is the fractional elimination rate, that is, the fraction of the recirculating pool that is eliminated from the pool daily. This fraction can be determined from: ki = In 2/lymphocyte survival half-life in days. If a patient had a bulk loss process such as gastrointestinal lymphocyte loss, superimposed on the normal mechanism of lymphocyte turnover, with the fraction of the daily bulk lymphocyte loss defined as k2, the new pool size P2 then becomes: P2 = s2/(ki + k2), and the ratio of the lymphocyte pool size of the patient with bulk loss to that of the normal would be From these considerations it is apparent that both the pathway of recirculation and the life span of the recirculating, long-lived lymphocyte population make this population particularly susceptible to the effects of chronic gastrointestinal lymph loss, and result in its relative depletion from the peripheral blood. Therefore, the defective in vitro transformation of peripheral blood lymphocytes in patients with intestinal lymphangiectasia can be most easily explained by depletion of the longlived, recirculating population of lymphocytes, and at the same time, the more normal proliferative response of cells obtained from chylous effusions can be explained by the relative enrichment of this cell population with recirculating cells which enter the effusion directly with the chylous intestinal lymph. Thus, intestinal lymphangiectasia represents an apparent clinical analogue of the rodents with prolonged thoracic duct drainage, and provides evidence that, just as in rodents, the peripheral lymphocyte pool of man consists of at least two functionally distinct populations.
Deficient in vitro lymphocyte blast transformation has been described in many other diseases characterized by impaired delayed hypersensitivity and clinical anergy. Mechanisms responsible for deficient in vitro transformation in these diseases include abnormal stem-cell development as in Swiss-type agammaglobulinemia (28) and an absence of a normal thymus as in the DiGeorge syndrome (29, 30) . Intestinal lymphangiectasia is unlike these or other developmental immune deficiency states, however, in that the immune deficiency characteristic of this disease results from shortened survival rather than from defective production of effector components. Structural lymphatic abnormalities in the mucosa of the small bowel resulting in the loss of lymphocyte-rich lymph into the gastrointestinal tract appear to be re-sponsible for the short survival of both immunoglobulins and lymphocytes. Patients with intestinal lymphangiectasia thus represent a new mechanism of defective in vitro lymphocyte blast transformation:-the loss of the long-lived, recirculating lymphocyte population which is apparently necessary for normal in vitro lymphocyte proliferative responses.
